Aristotle Capital Management, LLC, an investment management company, released its “Core Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The fund returned 14.69% in the second quarter of 2026, slightly trailing the 15.20% gain of the S&P 500 Index as market performance remained highly concentrated in artificial intelligence (AI)-related […]

Boston Scientific completes multi year buyback and what it means for investors Boston Scientific (BSX) has completed a multi year share repurchase program, buying back 39,922,436 shares for about US$2.0b. The completed buyback represents 2.69% of the company’s shares. This update provides an additional data point on how Boston Scientific is allocating capital and managing its share count. It also offers a clearer backdrop for assessing recent stock performance and earnings expectations. See...

In the June quarter, Boston Scientific completed a share repurchase of 39,922,436 shares, equal to 2.69% of its stock, for US$2,000.11 million under the buyback first announced in December 2020, while quarterly results highlighted underperformance in U.S. Electrophysiology and Watchman alongside lower 2026 organic sales growth guidance. Although the CHAMPION-AF trial met all clinical endpoints, it did not act as a meaningful catalyst for the business outlook, and the contrast between bullish...

Boston Scientific stock has fallen about 50% over the past year, yet valuation checks and an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach both suggest the shares may be trading below what the fundamentals imply. That gap between weak recent returns and an undervalued read is now front of mind for anyone looking at the current US$51.83 share price. Over the last 12 months, Boston Scientific has declined 49.8%, which puts recent investor sentiment and the current...

Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” second quarter of 2026 investor letter. A copy of the letter can be downloaded here. The fund returned 16.83% in the second quarter of 2026, outperforming the S&P 500’s 15.20% gain. Performance was supported by holdings in Information Technology and Communication Services, as […]

Options price a band whose floor sits below anything the stock has touched in the past year, and the company's own recovery timetable lands after that window closes.

Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the ‘TCW Concentrated Large Cap Growth Fund.’ A copy of the letter can be downloaded here. During the second quarter, AI monetization, a fragile Middle East ceasefire, and a Federal Reserve leadership transition were the significant events. All major indices ended higher, […]

Edwards' 14% three-month rally reflects broad structural-heart growth, but its premium valuation raises the bar for execution.

ABT's EPD growth is fueled by emerging-market strength, broad branded generics and healthcare demand, with biosimilars adding opportunities.

Two stalled franchises forced the guidance cut, and they sit outside the three quarters of revenue management still expects to grow at its long-run pace, with the shares now near the bottom of their decade on sales.

Habiger's $100,000 purchase expanded his direct holdings by 14%, signaling confidence despite the stock's recent weakness. The acquisition came as shares traded near their lowest levels in over a year.

Mahoney expanded his equity stake by 13% following a -54% one-year stock decline. His combined holdings now total ~1.6 million shares valued at $78.08 million.

Abbott's Medical Devices growth, EPD momentum and improving Nutrition support its outlook, but China risks, costs and valuation warrant caution.

WATCHMAN and Electrophysiology headwinds force guidance cut despite solid organic growth.

Boston Scientific (NYSE: BSX) has initiated multiple product recalls covering cardiac ablation generators and vascular access sheaths due to labeling discrepancies and air embolism risks. The recalls affect a broad mix of devices used in cardiac and vascular procedures across several international markets. Regulators and hospitals are assessing the implications for device safety protocols, clinical workflows, and future use of the impacted products. Product safety questions can prompt...

AngioDynamics' Med Tech growth and reimbursement gains strengthen its outlook, but tariffs, rising costs and execution risks keep the buy case uncertain.

AngioDynamics' fiscal 2027 outlook hinges on Med Tech growth offsetting flat device sales as tariffs, spending and losses pressure margins.

AngioDynamics' 33.5% three-month rally rests on Med Tech growth, but valuation, tariffs and negative earnings keep execution risks high.

Boston Scientific's 2026 guidance cut tests its recovery as WATCHMAN weakness, EP share losses and delayed margin gains push a broader rebound toward 2028.

Boston Scientific's cheaper valuation offers upside, but weaker guidance, share losses, higher debt and delayed catalysts favor patience.

Despite nearly doubling revenues to $21+ billion in the past 5 years, BSX has dropped 60% in the past year

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Abbott Laboratories has shed billions in market value this year while the broader market climbed, yet one analyst on Wall Street sees a dramatically different story unfolding beneath the surface of the company's bruised financials.

Medical device company Boston Scientific (NYSE:BSX) announced better-than-expected revenue in Q2 CY2026, with sales up 7.5% year on year to $5.44 billion. On the other hand, next quarter’s revenue guidance of $5.27 billion was less impressive, coming in 2.2% below analysts’ estimates. Its non-GAAP profit of $0.86 per share was 3.8% above analysts’ consensus estimates.

Roblox downgraded, Quanta Services upgraded: Wall Street's top analyst calls

After a week of wild swings that rattled portfolios and left investors guessing, Wall Street analysts are already reshuffling their ratings on Friday morning, with some surprising cuts and upgrades across sectors from utilities to gaming that could reshape how you think about your positions.

Boston Scientific (BSX) reported Q2 revenue and EPS that beat expectations but lowered its full-year

BSX faces WATCHMAN and EP pressures as management cuts outlook while highlighting cost savings and new product catalysts for future growth.

Boston Scientific underperformed the broader market, though analysts remain optimistic, citing strong earnings execution, innovation, and meaningful upside from current levels.

Analyst fair value for Boston Scientific has shifted from US$75.00 to US$72.25, pointing to a modest reset in price targets. This change lines up with recent research that lowers expectations for Watchman and electrophysiology while still recognizing strengths across the broader portfolio and generally positive ratings. As you read on, you will see how these moving targets, both bullish and bearish, shape the evolving Boston Scientific story and what to watch next. Stay updated as the Fair...

Boston Scientific recently reported its second-quarter 2026 results, showing sales of US$5,442 million and net income of US$907 million, alongside issuing a recall of its Rapid Refill Continuous Injection System and initiating a multi-year global restructuring plan aimed at cost efficiencies. While the company raised full-year 2026 net sales growth expectations to approximately 5.5%–6.5%, it also outlined a restructuring program costing up to US$800 million and targeting around US$500...

Moby summary of Boston Scientific Corporation's Q2 2026 earnings call

Boston Scientific (NYSE:BSX) reported second-quarter 2026 revenue growth at the high end of its guidance range and adjusted earnings per share above expectations, but lowered its full-year outlook as it faces slowing demand in its WATCHMAN left atrial appendage closure business and increased competi

Healthcare stocks were lower late Wednesday afternoon, with the NYSE Healthcare Index down 0.3% and

Boston Scientific Corp (BSX) reports a robust Q2 with 7% organic sales growth and a 15% increase in adjusted EPS, despite challenges in some segments.

Healthcare stocks were slightly lower Wednesday afternoon, with the NYSE Healthcare Index down 0.1%

Boston Scientific Corp (NYSE:BSX, XETRA:BSX) reported second quarter results that exceeded analyst expectations for revenue and adjusted earnings, while raising its full-year sales outlook. The medical device company posted adjusted earnings per share of $0.86, ahead of the $0.83 consensus...

Boston's tempered 2026 outlook is likely due in part to its recently announced plans to initiate a global restructuring programme.

Boston Scientific (BSX) lowered its full-year guidance below Wall Street's estimates on Wednesday, c

Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

The medical device maker topped second-quarter expectations but now sees full-year adjusted EPS of $3.28 to $3.32, down from a prior range of $3.34 to $3.41

BSX beats Q2 earnings and revenue estimates as cardiovascular growth, strong APAC and LACA sales, and margin expansion lift shares in pre-market.

Boston Scientific (NYSE:BSX) shares rose more than 3% in pre-market trading on Wednesday after the medical device manufacturer reported second-quarter earnings and revenue that exceeded Wall Street expectations, supported by broad-based growth across its business. The company reported earnings of $0.

Boston Scientific (BSX) delivered earnings and revenue surprises of +3.61% and +1.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The main US stock measures were mostly trending higher in Wednesday's premarket activity as traders

Boston Scientific logged higher second-quarter results and cut its full-year outlook as it begins a new restructuring plan announced earlier this week.

July 29 (Reuters) - Medical device maker Boston Scientific on Wednesday lowered its annual profit forecast, citing pressure on its Watchman heart device business.

Investing.com -- Shares in Boston Scientific rose over 3% in premarket trading Wednesday after the medical device maker reported second-quarter earnings and revenue that topped Wall Street estimates.